Share Name Share Symbol Market Type Share ISIN Share Description
Diaceutics Plc LSE:DXRX London Ordinary Share GB00BJQTGV64 ORD GBP0.002
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -2.00 -1.67% 117.50 115.00 120.00 119.50 117.50 119.50 21,187 08:34:23
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology - - - - 82

Diaceutics Share Discussion Threads

Chat Pages: 1
a profit upgrade drove shares in Diaceutics 15 per cent higher to 117p, with the precision medicine group saying its 2019 earnings will now be ahead of market expectations after a strong finish to the year.
The reason why there's probaly so little interest is it looks like another massively over priced ipo from what i can see in the admission document. Revenue for 2018 was £10.4. a 40% increase on 2017. operating profit was £1.2m operating margin 11.5% decent but nothing special. If they grow sales next year at 40% again then revenue is £14.6m assuming a similar margin then operating profit will be around 1.7m again assuming no debt after the ipo and ignoring tax and D&A £1.7m equates to around 2.5p/share at an operation level (67m shares) my best guess would be it will deliver eps less than 2p all told. If it gets to half the current share price it may attract my attention. woody
but hasn't Roche bought up its own lab testing company so it will have access to results on their patients: if other large pharma did the same would that undermine diaceutics?
Surprised there's not more interest in this great little company
Diaceutics sets out stall to dominate precision medicine test market Sales growth has been 40-50% a year over the past five years and the company hopes that the investments made with the placing money will continue that trend. Revenues last year (2018) jumped to £10.4mln from £7.4mln, with profits rising 82% on an underlying basis to £1.9mln. The business has been profitable from the first day it was established. hxxps://
!YOUTUBEVIDEO:01a2yFBGZko: Diaceutics has built a global data lake of diagnostic testing information, curating data from over 2500 labs around the globe. Our data analytics services, including Landscape, Tracking and Primary Market Research, leverage the diagnostic testing information to provide data-driven insights to drive seamless integration of diagnostic tests into treatment pathways. Diaceutics Investor Centre
Chat Pages: 1
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200118 12:49:27